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Introduction
Apelin-13 (APL-13) is a member of an endogenous pep-
tide’s family (APLs) with powerful inotropic and cardio-
protective properties. APLs bind to the dedicated receptor
APJ-R, a member of the G protein-coupled receptor
superfamily, all being widely expressed in the cardiovascu-
lar system. We have already shown that APL-13 infusion,
was protective against LPS-induced myocardial dysfunc-
tion and death vs. dobutamine [1]. Furthermore, we have
shown that, C-terminal Phe(13) modification of APL-13
by unnatural amino acids can change ligand binding and
APJ-R signaling [2].
Objectives
Understanding the beneficial impact of APL-13 on LPS-
induced myocardial injury vs. dobutamine, and assessing
functional and biological effects of a new selected linear
APL-13 analog with enhanced affinity, and their impact
in the context of sepsis.
Methods
Myocardial dysfunction was induced by intra-peritoneal
injection of LPS (E. Coli 055:B5, 10 mg/kg) or Cecal
Ligature and Puncture (CLP) in male Sprague-Dawley
rats. Myocardial injury was biologically evaluated by
analyzing of different cellular pathway of apoptosis and
inflammation by Western blot. Myocardial function was
assessed ex-vivo by Langendorff and in vivo by echocar-
diography by comparing APL-13 to Tyr(Obn). Tyr(OBn)
(13) substitution led to a 60-fold increase in binding
affinity vs. APL-13 [2].
Results
LPS-challenged rats treated with APL-13 exhibited a
clear reduction of both apoptosis (cleaved caspase-3,
BAX/BCL-2 ratio) and inflammation (iNOS and MIF)
markers, with significant alterations in the Akt/GSK3b/
mTor and P38/Erk pathways underscoring the cardio-
protective effect of APLs. Organic Langendorff assays
confirmed cellular data [2] in that enhanced affinity
confers to Tyr(Obn) analog a more effective and potent
inotropic activity than APL-13, as shown by the
increased left ventricular developed pressure (LVDP)
(% baseline, 1pM : APL-13, 8 ± 13 vs. Tyr(Obn), 60 ±
15 ; p < 0.05), (30pM : APL-13, 124 ± 25 vs. Tyr(Obn),
372 ± 106 ; p < 0.05). APLs sensibility was increased in
8h CLP-challenged hearts, as it was in 24h LPS-challenged
hearts [1], suggesting upregulation of the myocardial apeli-
nergic pathway during polymicrobial sepsis. Indeed, CLP
model of sepsis was characterized at 8h by a reduced car-
diac output (Sham, 170 ± 3 vs. CLP, 99 ± 5 ml/min, p <
0.05) with an increased parietal thickness (Sham, 0.15 ±
0.002 vs. CLP, 0.23 ± 0.003 cm, p < 0.05) in vivo.
Conclusions
APLs are new safer supporting drugs in sepsis. Chemical
modifications can optimize the inotropic potency of
APLs opening a novel field of therapeutic opportunities.
Ongoing works are to evaluate the functional effect of
these new analogs in vivo, with Pressure-Volume curve
device, and to further test their comparative cardiopro-
tective potential during experimental CLP sepsis.
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